

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



The United Laboratories International Holdings Limited

聯邦制藥國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3933)

PROGRESS IN CLINICAL TRIAL OF THE GROUP'S PRODUCT UBT251 INJECTION

This announcement is made by The United Laboratories International Holdings Limited (the "Company") on a voluntary basis.

The board of directors (the "Board") of the Company is pleased to announce that the Phase II clinical trial (the "Study") of UBT251 Injection, a Class 1 innovative drug independently developed by The United Bio-Technology (Hengqing) Co., Ltd. ("United Biotechnology"), a wholly-owned subsidiary of the Company, has been completed in Chinese patients with Type 2 diabetes.

This Study adopted a randomized, double-blind, placebo- and semaglutide-controlled design, and enrolled a total of 211 Chinese patients with Type 2 diabetes (managed with lifestyle intervention alone or in combination with metformin). At baseline, the patients had a mean glycated hemoglobin ("HbA_{1c}") of 8.12%, a mean body weight of 80.1 kg, and a mean body mass index ("BMI") of 29.1 kg/m². Patients were randomly assigned to receive once-weekly subcutaneous injections of UBT251 at doses of 2 mg, 4 mg, 6 mg, placebo, or semaglutide 1 mg for 24 consecutive weeks. The primary endpoint of the Study was the change in HbA_{1c} from baseline after 24 weeks of treatment.

The results of the Study showed that after 24 weeks of treatment, the UBT251 groups achieved a mean HbA_{1c} reduction of up to 2.16%, which was significantly better than that observed in the semaglutide group (1.77%) and the placebo group (0.66%). The mean body weight reduction in the UBT251 groups reached up to 9.8%, compared with 4.8% in the semaglutide group and 1.4% in the placebo group. In addition, compared with the placebo group, UBT251 showed improvements in key secondary endpoints, including waist circumference, blood pressure and blood lipid levels.

In the Study, UBT251 showed good safety and tolerability. The safety and tolerability profile of UBT251 appeared consistent with what has been observed in other clinical trials with triple-G agonists.

The Phase II clinical trial of UBT251 Injection in patients with Type 2 diabetes achieved the expected results, supporting its progression to the next stage of clinical study. The Company will subsequently initiate a Phase III clinical trial in Chinese patients with Type 2 diabetes in a timely manner.

ABOUT UBT251

UBT251 is a long-acting triple-target receptor agonist of GLP-1 (glucagon-like peptide-1)/GIP (glucose-dependent insulintropic polypeptide)/GCG (glucagon). To date, the Company has been approved to conduct clinical trials in China and/or the United States for multiple indications including adult type 2 diabetes, overweight/obesity, chronic kidney disease (“CKD”) and metabolic dysfunction-associated steatohepatitis (“MASH”). The Company is the first enterprise in China and the second in the world to be approved for clinical trials of a long-acting triple agonist of GLP-1R/GIPR/GCGR prepared by chemical synthesis polypeptide method.

In March 2025, United Biotechnology and the Company entered an exclusive license agreement with Novo Nordisk A/S for UBT251.

By Order of the Board
The United Laboratories International Holdings Limited
Tsoi Hoi Shan
Chairman

Hong Kong, 25 March 2026

As at the date of this announcement, the Board comprises Mr. Tsoi Hoi Shan, Mr. Leung Wing Hon, Ms. Choy Siu Chit, Mr. Fang Yu Ping, Ms. Zou Xian Hong and Ms. Zhu Su Yan as executive directors; and Mr. Chong Peng Oon, Prof. Song Ming and Dr. Fu Qiushi as independent non-executive directors.